Human papillomavirus is responsible for 99 percent of all cervical cancer.
Two specific types, HPV 16 and HPV18, account for 70 percent of these cases.1,2
In ATHENA, the largest-ever study of cervical cancer screening practices, more than 47,000 women were tested for high-risk HPV types using the cobas® HPV Test. The study proved that HPV screening was more effective than Pap tests in both detecting and predicting high-grade cervical disease.
Roche is committed to helping change the standard of HPV screening to give women everywhere the best chance to prevent cervical cancer.